Lyell Immunopharma to Participate in BofA Securities Health Care Conference
May 07 2024 - 4:05PM
Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical‑stage T-cell
reprogramming company advancing a diverse pipeline of cell
therapies for patients with solid tumors, today announced that
members of its senior management team will participate in the
BofA Securities 2024 Health Care Conference on Tuesday,
May 14 at 8:40 am PT.
A live webcast of the presentation can be
accessed through the Investors section of the Company's website at
www.lyell.com. Following the live presentation, a replay of the
webcast will be available on the Company's website following the
presentation date.
About Lyell Immunopharma,
Inc.
Lyell is a clinical-stage T-cell reprogramming
company advancing a diverse pipeline of cell therapies for patients
with solid tumors. Lyell is currently enrolling a Phase 1 clinical
trial evaluating a ROR1-targeted CAR T-cell therapy in patients
with relapsed refractory triple-negative breast cancer (TNBC) and
non-small cell lung cancer (NSCLC) and a second Phase 1 clinical
trial evaluating reprogrammed tumor infiltrating lymphocytes (TIL)
in patients with advanced melanoma, NSCLC and colorectal cancer.
The technologies powering its product candidates are designed to
address barriers that limit consistent and long-lasting responses
to cell therapy for solid tumors: T-cell exhaustion and lack of
durable stemness, which includes the ability to persist and
self-renew to drive durable tumor cytotoxicity. Lyell is applying
its proprietary ex vivo genetic and epigenetic reprogramming
technologies to address these barriers in order to develop new
medicines with improved durable clinical outcomes. Lyell is based
in South San Francisco, California with facilities in Seattle and
Bothell, Washington. To learn more, please
visit www.lyell.com.
Contact:Ellen RoseSenior Vice
President, Communications and Investor Relationserose@lyell.com
Lyell Immunopharma (NASDAQ:LYEL)
Historical Stock Chart
From Apr 2024 to May 2024
Lyell Immunopharma (NASDAQ:LYEL)
Historical Stock Chart
From May 2023 to May 2024